NCT00631475View on ClinicalTrials.gov

Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443

PHASE3CompletedINTERVENTIONAL

Enrollment

128

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

April 30, 2010

Study Completion Date

May 31, 2010

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

Bosentan

"For patients who were administered Bosentan during BUILD 3 (NCT00391443):~continue on same dose~For patients who were administered placebo during BUILD 3 (NCT00391443):~Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs \< 90 lbs.)"